India's SII could resume Covishield shot production as COVID cases rise

Reuters · 04/12/2023 11:32
India's SII could resume Covishield shot production as COVID cases rise

- The Serum Institute of India (SII) could resume production of the Covishield COVID-19 vaccine, a company spokesperson said on Wednesday, as infections rise in the country.

The world's biggest vaccine maker already has a stock of 6 million doses of Covovax, a version of a Novavax NVAX.O vaccine, the spokesperson added. Covishield is a version of an AstraZeneca AZN.L shot.


(Reporting by Sakshi Dayal; Editing by Krishna N. Das)

((Sakshi.Dayal@thomsonreuters.com;))